REG - CVS Group plc - Commencement of Share Buyback Programme

CVSAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260526:nRSZ6170Fa&default-theme=true

RNS Number : 6170F  CVS Group plc  26 May 2026

For Immediate Release
 
 
  26 May 2026

 

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Commencement of Share Buyback Programme

 

As separately announced today, CVS, the UK listed veterinary group and a
leading provider of veterinary services, is launching a share buyback
programme to purchase ordinary shares of 0.2 pence each ("Ordinary Shares")
and has allocated up to £50 million to the buyback programme (the "Share
Buyback Programme").

 

The purpose of the Share Buyback Programme is to both return surplus capital
to shareholders and reduce the Group's share capital pursuant to its capital
allocation policy. As such, all Ordinary Shares repurchased by the Group under
the Share Buyback Programme will be cancelled.

 

CVS has entered into agreements with each of Peel Hunt LLP ("Peel Hunt") and
Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg") to
purchase Ordinary Shares up to a maximum aggregate consideration (excluding
expenses) of up to £50 million under the Share Buyback Programme. Peel Hunt
and Berenberg will act as riskless principals and will make trading decisions
concerning the timing of the purchases of Ordinary Shares independently of the
Company.

 

The purchase of Ordinary Shares will be carried out on the London Stock
Exchange and other trading venues. Any purchases of Ordinary Shares by the
Company will be conducted in accordance with the general authority to purchase
Ordinary Shares granted by its shareholders at the Company's Annual General
Meeting on 18 November 2025, pursuant to which the maximum number of shares
which remain available for purchase under the Share Buyback Programme is
6,040,012. The Share Buyback Programme will be conducted in accordance with
Chapter 9 of the Financial Conduct Authority's Listing Rules and
with European Union (EU) Regulation No 596/2014 ("MAR") and the MAR buyback
technical standards (Commission Delegated Regulation (EU) 2016/1052) (the
"Technical Standards"), both of which form part of Retained EU Law as defined
in the European Union (Withdrawal) Act 2018.

 

Any purchase of Shares pursuant to the Share Buyback Programme will be
announced by no later than the end of the 7th daily market session following
the calendar day on which such transaction occurred, as required by MAR.

 

The Share Buyback Programme is expected to be completed by 24 November 2026.

 

 

 

 Contacts
 CVS Group plc                                via FGS Global

 Richard Fairman, Chief Executive Officer

 Robin Alfonso, Chief Financial Officer

 Paul Higgs, Chief Veterinary Officer

 Charlotte Page, Head of Investor Relations

 

 FGS Global           +44 (0)207 251 3801
 Faeth Birch          cvsgroup@fgsglobal.com

 Charlie Chichester

 

 
 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk) )

CVS Group is a leading provider of veterinary services, operating in the UK
and Australia, listed on the Main Market of the London Stock Exchange.  CVS
is focused on providing high-quality clinical services to its clients and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and
3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRAKPBQCBKDBPB



            Copyright 2019 Regulatory News Service, all rights reserved